Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Biotech
Vivoryon's Alzheimer's asset suffers 2nd phase 2 fail
Vivoryon CEO Frank Weber, M.D., said this failure across the board in Alzheimer’s “confirm the data seen in VIVIAD and are therefore not unexpected.”
James Waldron
Dec 9, 2024 7:10am
Maze finds its way to $115M series D
Dec 3, 2024 12:42pm
Jade pockets Aerovate in reverse merger
Oct 31, 2024 3:03pm
Gene therapy reduces harmful protein levels in mouse kidneys
Oct 29, 2024 12:54pm
Analysts hail Vera's kidney drug as potential 'functional cure'
Oct 28, 2024 9:27am
GSK and Cambridge scientists join forces in $65M immune R&D deal
Oct 22, 2024 3:30pm
